Ruthenium Peptide Bioconjugates for Photoactivated Chemotherapy
One of the most severe limitations of current anticancer chemotherapy are the serious side effects caused by toxic drugs affecting not only tumors but also healthy organs. Local activation of drugs by light irradiation of the tumo...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PhoRAu
Photochemistry and radiolabelling of gold III anticancer pr...
158K€
Cerrado
RUPROLIGHT
Light activatable ruthenium based anticancer prodrugs
1M€
Cerrado
PID2021-127187OB-C22
ESTRATEGIAS AVANZADAS EN EL DISEÑO DE FOTOSENSIBILIZADORES B...
91K€
Cerrado
Ru4EYE
Ruthenium based photoactivated chemotherapy against eye canc...
150K€
Cerrado
PHOTORUACD
Novel Photodissociable Ruthenium Based Anticancer Drugs
178K€
Cerrado
PERSEUS
2D Material-Based Multiple Oncotherapy Against Metastatic Di...
3M€
Cerrado
Información proyecto pepRu4PACT
Duración del proyecto: 23 meses
Fecha Inicio: 2023-03-01
Fecha Fin: 2025-02-28
Líder del proyecto
UNIVERSITEIT LEIDEN
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
One of the most severe limitations of current anticancer chemotherapy are the serious side effects caused by toxic drugs affecting not only tumors but also healthy organs. Local activation of drugs by light irradiation of the tumor is a promising approach to control where the toxicity is delivered. Metal complexes are well suited for photoactivated chemotherapy, but their activation wavelength is often too low to afford high tissue penetration of light; also, their ability to enter cancer cells is often controlled by lipophilicity tuning, which is unselective; finally, their phototoxicity often relies on oxygen-dependent mechanisms, while many tumor tissues show low dioxygen concentrations. The aim of this proposal is to develop new metallodrugs that are activated by red or near-infrared light, enter cells by controlled mechanisms, and deliver strong phototoxicity to cancer cells also under low oxygen conditions. The design is based on connecting multiple Ru(II) metal complexes to a biologically active antitumoral peptide. The ruthenium complexes will have a tuned coordination environment to allow red/near-IR light activation; meanwhile, the peptides will rely on methionine residues to coordinate ruthenium, and allow controlled cellular uptake of the prodrug into cancer cells. Both components will cage each other in the dark, thus affording low toxicity; while light-induced cleavage of the ruthenium-thioether bonds will release two bioactive components, which will kill cancer cells. The novelty of this proposal is to combine metal-based photoactivated chemotherapy with therapeutic peptides to enhance phototoxicity by creating synergies between both photoproducts. By combining light activation, resulting in timely- and spatially-resolved toxicity release, and bioactive peptides, which will improve uptake in cancer cells, this project will deliver new fundamental knowledge on the interaction between peptides and metals, and between metallopeptides and cells.